Regenerative medicine company Regeneus (ASX:RGS) has announced that its CEO Karolis Rosickas has purchased over 3.8 million shares in the company.
The company said the purchase of 3,836,366 fully paid ordinary shares off-market was transacted at the volume-weighted average price (VWAP) of $0.04 per share, equating to $153,454.64.
The shares were purchased in accordance with the company’s Securities Trading Policy and Mr Rosickas was not in possession of any market-sensitive information not otherwise disclosed to the market.
“I have a firm conviction in the value of Regeneus’ differentiated technology and its clinical pipeline. Cell and gene therapies are becoming a more prominent modality in the pharmaceuticals industry, and Regeneus is at the forefront in developing and commercialising novel and highly efficacious treatments for patients,” said Mr Rosickas.
The company said the investment demonstrates the support and conviction of its leadership team as it continues to deliver material progress of its clinical pipeline towards the commercialisation of its two leading stem cell technologies, Progenza and Sygenus.
